Navigation Links
Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
Date:12/14/2007


Worldwide Rights for All Potential Uses, Excluding U.S. and Japan

No Other Existing Therapeutic Treatment for Celiac Disease

BASINGSTOKE, England and PHILADELPHIA, December 14 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, today announces that it has acquired the worldwide rights, excluding the U.S. and Japan, to AT-1001 from Alba Therapeutics Corporation (Alba). AT-1001 is Alba's lead inhibitor of barrier dysfunction in various gastrointestinal disorders that is currently in Phase 2 development for the treatment of Celiac disease. Shire has acquired rights to all uses for AT-1001, which may also be studied for the treatment of Crohn's disease and other indications.

Matthew Emmens, Chief Executive Officer, commented: "The licensing of AT-1001 from Alba is a natural fit to our growing portfolio of gastrointestinal products. This product will be marketed to specialist physicians and we would expect to use our existing European sales force that is currently establishing relationships and expertise in the GI area through the marketing of MEZAVANT XL."

Financial terms of the license are geared to the successful development and commercialization of the product. Shire will pay Alba an upfront license fee of $25 million and further development and sales-based milestones totalling to a maximum of $300.5M should the product reach blockbuster status. Shire will also pay royalties on net sales of the product, with tiered, single or double digit royalty rates.

Alba and Shire will form a joint development committee to monitor R&D activities of AT-1001. Alba will fund all development until AT-1001 has completed Proof of Concept, which is expected to be in the first half of 2009, after which Shire and Alba will share equally development costs under a joint development plan.

About Celiac disease:

Celiac disease is a T-cell mediated auto-immune dis
'/>"/>

SOURCE Shire plc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
2. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
3. Shire Divests Non-Core Product Portfolio to Almirall
4. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
5. David Mott Appointed Non Executive Director at Shire
6. Shire plc: Board Changes
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. ATS Medical Expands Open Pivot Heart Valve Offerings
9. SAFC Expands Hi-Potency API Manufacturing and Introduces Solid-Form Testing at Its Madison Facility
10. BioLife Solutions Expands Scientific Advisory Board
11. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 23, 2014 With the ability to record ... for more than 15 minutes, Fastec Imaging has brought the ... high speed imaging. “Finally, a high speed camera that can ... in our everyday lives.” proclaims Matt Kearney, VP of Sales ... been to demystify and simplify the traditionally complicated workflow of ...
(Date:7/23/2014)... 23, 2014 a2z Inc. announces that ... App, AACC Pathfinder, in its 2014 Annual Meeting ... meeting is planned for July 29-31, 2014 in Chicago, ... be to connect with global leaders in clinical chemistry, ... other areas of breaking science in laboratory medicine. , ...
(Date:7/23/2014)... MA (PRWEB) July 23, 2014 ... of innovative and comprehensive consultancy and pharma training ... Excellence and Safety (ACRES) , a non-profit integrating ... to build and maintain a global system for ... alliance collaboration to improve the expertise of industry ...
(Date:7/22/2014)... July 22, 2014 The Board of Directors of ... has declared a quarterly dividend of 54.5 cents per common ... on September 9, 2014. The indicated annual dividend rate is ... BD is a leading medical technology company that partners with ... pressing and evolving health needs. Our innovative solutions are focused ...
Breaking Biology Technology:Fastec Imaging Introduces the First High Speed Camcorder 2Fastec Imaging Introduces the First High Speed Camcorder 3AACC Enhances Attendee Experience at Its 2014 Annual Meeting & Clinical Lab Expo with a2z-Powered ChirpE Photo Booth and Mobile App 2AACC Enhances Attendee Experience at Its 2014 Annual Meeting & Clinical Lab Expo with a2z-Powered ChirpE Photo Booth and Mobile App 3Astra Nova and ACRES Partner on Quality and Access of Training for Research Professionals 2Astra Nova and ACRES Partner on Quality and Access of Training for Research Professionals 3
... This release is available in French . Physicists ... energy involved in adding electrons to semi-conductor nanocrystals, also known ... and other areas of science. Dr. Peter Grtter, McGill,s Associate ... that his research team has developed a cantilever force sensor ...
... EDMONTON , May 11 ... company focused on developing medical device,products for use ... it has,received regulatory concurrence from the United States ... product, Occlusin(R) 500 Artificial,Embolization Device (OCL 500) in ...
... ORLANDO, Fla. , May 11 GeneLink, Inc. (OTC Bulletin ... quarter ended March 31, 2010 . , , ... , , , ... Quarterly operating loss reduced by 14% over Q4 2009 Comparable quarter gross profit improvement ...
Cached Biology Technology:Quantum move toward next generation computing 2IMBiotechnologies Receives FDA Clearance to Market Occlusin(R) 500 Biodegradable Microspheres in the U.S. 2IMBiotechnologies Receives FDA Clearance to Market Occlusin(R) 500 Biodegradable Microspheres in the U.S. 3GeneLink Reports First Quarter Gains 2
(Date:7/22/2014)... National Institute of Standards and Technology (NIST), working ... improved technique for analyzing biological cells and tissues ... NIST technique is an advanced form of the ... delivers signals that are 10,000 times stronger than ... stronger than obtained from comparable "coherent Raman" instruments, ...
(Date:7/22/2014)... Rochelle, NY -- Stem cells offer much promise for ... approaches stem cell survival is poor, limiting their effectiveness. ... the survival and optimize their therapeutic function after transplantation, ... Open Access , a peer-reviewed journal from Mary Ann ... the BioResearch Open Access website . ...
(Date:7/22/2014)... July 22, 2014 BGI Tech Solutions Co., ... world,s largest genomics organization, announced today the global ... service based on Complete Genomics, industry-leading platform. This ... SNP validation, and is available at reduced prices ... highly regarded in the industry for providing proprietary ...
Breaking Biology News(10 mins):Enhanced NIST instrument enables high-speed chemical imaging of tissues 2Enhanced NIST instrument enables high-speed chemical imaging of tissues 3BGI Tech launches human whole exome sequencing service on complete genomics' advanced platform 2
... developing bipolar disorder depends in part on the combined, small ... brain, none of which is powerful enough to cause the ... the enzyme produced by one of these genes could lead ... was conducted by scientists at the National Institutes of Health's ...
... their effects on fat development, researchers have discovered that ... mice without some of the side effects attributed to ... harmine, was first isolated more than 150 years ago ... around the world, the team reports in the May ...
... it express who we are, but is it really possible to ... to that question seems to be related to fashion and glamour, ... Mexico and the Buck Institute in the USA, were able to ... In biology, the capacity to establish the function of a molecule, ...
Cached Biology News:Genetic roots of bipolar disorder revealed by first genome-wide study of illness 2Genetic roots of bipolar disorder revealed by first genome-wide study of illness 3Fat screen delivers plant-derived chemical with antidiabetic effects 2
Tissue culture grade....
Tris-Hepes kit of BG-163 & BG-165 (order number BG-166)...
... ideal for both radioactive and nonradioactive labeling ... Provides five pre-mixed nucleotide solutions for flexibility ... 8 cpm/g control DNA using [-32P]-dCTP ... performance of the system Labels 1 ...
Activating Agents, 7-azabenzotriazol-1-yloxy-tris-(pyrrolidino)phosphonium hexafluorophosphate...
Biology Products: